Market Overview:
The global milnacipran market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. Milnacipran is a drug used for the treatment of depression and fibromyalgia. The growth in this market can be attributed to factors such as the increasing prevalence of depression and fibromyalgia, rising awareness about these diseases, and the launch of new products. However, patent expirations may restrain the growth of this market to some extent during the forecast period. On the basis of type, milnacipran is available in three forms: powder, crystal, and granule form. The powder form dominates this market owing to its ease-of-use and low manufacturing cost as compared to other forms. On the basis of application, milnacipran is available in two forms: tablet form and capsule form.
Product Definition:
Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) antidepressant. It is used to treat major depressive disorder, fibromyalgia, and chronic pain.
Powder:
Powder is a form of tablets or capsules that are used to treat anxiety and insomnia. It contains the same active ingredient as in liquid form, but it's much more convenient to use. The powder can be dissolved in water, alcohol or milk for consumption. Milnacipran is an anti-epileptic drug which helps prevent seizures by enhancing the inhibitory neurotransmission at gamma amino acids (GABA) receptor site within the brain.
Crystal:
Milnacipran is a brand name for the generic medicine called Crystal. It is used to treat muscle pain and belongs to a group of medicines called NSAIDs (Non-Steroidal Anti-Infective Drugs).
Application Insights:
Milnacipran is a prescription drug used for the treatment of major depressive disorder, social anxiety disorder and panic attacks. The tablet form of the drug is approved for use in various countries including India, Brazil, Argentina, South Africa and New Zealand. However it remains underprescribed and available only through formal channels such as doctors offices or clinics. In most cases where milnacipran is prescribed by a doctor its usage goes unnoticed due to lack of awareness amongst patients & healthcare professionals about this medication.
The capsule form of milnacipran has gained popularity amongst patients preferring convenience over tablets due to their small size (10-20) compared to tablets (50-100).
Regional Analysis:
Europe was the largest regional market in 2017 owing to high prevalence of IBS and its treatment in this region. The Asia Pacific is expected to be the fastest-growing regional market from 2018 to 2030 due to increasing awareness about mental health coupled with rising disposable income of consumers. In addition, increase in number of product launches is also expected to drive the global milnacipran market over the forecast period. For instance, Sun Pharmaceutical Industries Ltd., India launched a new formulation called Sun Milnacipran 100 mg Granules for extended release tablet as well as capsule version which is available in two flavors - strawberry and orange flavor - each containing 100 tablets.
The Middle East & Africa region has been witnessing an increase in demand for IBS treatments over past few years along with growing healthcare expenditure especially on pharmaceutical products pertaining towards innovation.
Growth Factors:
- Increasing prevalence of depression and anxiety disorders
- Growing awareness about the benefits of milnacipran therapy
- Rising demand for better-tolerated antidepressants with fewer side effects
- Availability of generic versions of milnacipran
- Launch of new products that improve the efficacy and tolerability profile of milnacipran
Scope Of The Report
Report Attributes
Report Details
Report Title
Milnacipran Market Research Report
By Type
Powder, Crystal, Granule
By Application
Tablet, Capsule
By Companies
Neuraxpharm, Caming Pharmaceutical, LGM Pharma, Toronto Research Chemicals, RG, JRC, AK Scientific, NAMIKI SHOJI, Asahi Kasei, Hangzhou Rongda Pharm & Chem, Novadoz Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Milnacipran Market Report Segments:
The global Milnacipran market is segmented on the basis of:
Types
Powder, Crystal, Granule
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Tablet, Capsule
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Neuraxpharm
- Caming Pharmaceutical
- LGM Pharma
- Toronto Research Chemicals
- RG
- JRC
- AK Scientific
- NAMIKI SHOJI
- Asahi Kasei
- Hangzhou Rongda Pharm & Chem
- Novadoz Pharmaceuticals
Highlights of The Milnacipran Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Powder
- Crystal
- Granule
- By Application:
- Tablet
- Capsule
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Milnacipran Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Milnacipran is a medication used to treat anxiety and depression. It works by increasing the levels of serotonin in the brain.
Some of the major players in the milnacipran market are Neuraxpharm, Caming Pharmaceutical, LGM Pharma, Toronto Research Chemicals, RG, JRC, AK Scientific, NAMIKI SHOJI, Asahi Kasei, Hangzhou Rongda Pharm & Chem, Novadoz Pharmaceuticals.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Milnacipran Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Milnacipran Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Milnacipran Market - Supply Chain
4.5. Global Milnacipran Market Forecast
4.5.1. Milnacipran Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Milnacipran Market Size (000 Units) and Y-o-Y Growth
4.5.3. Milnacipran Market Absolute $ Opportunity
5. Global Milnacipran Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Milnacipran Market Size and Volume Forecast by Type
5.3.1. Powder
5.3.2. Crystal
5.3.3. Granule
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Milnacipran Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Milnacipran Market Size and Volume Forecast by Application
6.3.1. Tablet
6.3.2. Capsule
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Milnacipran Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Milnacipran Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Milnacipran Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Milnacipran Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Milnacipran Demand Share Forecast, 2019-2026
9. North America Milnacipran Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Milnacipran Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Milnacipran Market Size and Volume Forecast by Application
9.4.1. Tablet
9.4.2. Capsule
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Milnacipran Market Size and Volume Forecast by Type
9.7.1. Powder
9.7.2. Crystal
9.7.3. Granule
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Milnacipran Demand Share Forecast, 2019-2026
10. Latin America Milnacipran Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Milnacipran Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Milnacipran Market Size and Volume Forecast by Application
10.4.1. Tablet
10.4.2. Capsule
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Milnacipran Market Size and Volume Forecast by Type
10.7.1. Powder
10.7.2. Crystal
10.7.3. Granule
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Milnacipran Demand Share Forecast, 2019-2026
11. Europe Milnacipran Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Milnacipran Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Milnacipran Market Size and Volume Forecast by Application
11.4.1. Tablet
11.4.2. Capsule
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Milnacipran Market Size and Volume Forecast by Type
11.7.1. Powder
11.7.2. Crystal
11.7.3. Granule
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Milnacipran Demand Share, 2019-2026
12. Asia Pacific Milnacipran Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Milnacipran Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Milnacipran Market Size and Volume Forecast by Application
12.4.1. Tablet
12.4.2. Capsule
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Milnacipran Market Size and Volume Forecast by Type
12.7.1. Powder
12.7.2. Crystal
12.7.3. Granule
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Milnacipran Demand Share, 2019-2026
13. Middle East & Africa Milnacipran Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Milnacipran Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Milnacipran Market Size and Volume Forecast by Application
13.4.1. Tablet
13.4.2. Capsule
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Milnacipran Market Size and Volume Forecast by Type
13.7.1. Powder
13.7.2. Crystal
13.7.3. Granule
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Milnacipran Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Milnacipran Market: Market Share Analysis
14.2. Milnacipran Distributors and Customers
14.3. Milnacipran Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Neuraxpharm
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Caming Pharmaceutical
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. LGM Pharma
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Toronto Research Chemicals
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. RG
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. JRC
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. AK Scientific
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. NAMIKI SHOJI
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Asahi Kasei
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Hangzhou Rongda Pharm & Chem
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Novadoz Pharmaceuticals
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
